) announced that its cobas 6800/8800 systems - two integrated and
fully automated molecular testing systems for blood and plasma
donor screening are commercially available in markets which accept
the CE mark.
Both the systems are designed for donor screening, viral load
monitoring, women's health and microbiology testing. The systems
enable labs to generate a high volume of results faster with fewer
manual steps, thereby improving laboratory operations. In addition,
the systems ensure a safe blood supply through better
The portfolio launched also includes the cobas p680 instrument
to support the creation of donor sample pools along with three
next-generation assays for donor screening - cobas MPX, cobas WNV
and cobas HEV. Roche plans to release a next-generation cobas DPX
test by the fourth quarter to complete the donor screening
We note that the systems are not currently available in the
Apart from providing therapeutic products and services for
diverse medical needs, Roche also focuses on innovative diagnostic
solutions for the early detection and treatment of diseases.
Roche has a broad portfolio of diagnostic tests with more than a
hundred high-quality Elecsys assays for immune testing along with a
new generation of fully automated cobas analyzers for improved
medical decision making, scheduling and efficiency.
We are impressed by Roche's efforts to strengthen its Diagnostic
Roche was in the news recently when it announced that it has
entered into a definitive merger agreement to acquire
California-based biotechnology company InterMune, Inc. (
) for $74.00 per share or $8.3 billion.
Roche currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the broader healthcare sector include
) and Gilead Sciences (
). Both sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis
INTERMUNE INC (ITMN): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.